Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Psychiatr Clin North Am ; 47(1): 229-253, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38302209

RESUMO

Traumatic experiences and sleep disturbances are both common in children and adolescents. Because of the reciprocal relationship between sleep complaints and trauma, a mental health evaluation should include not only an assessment of posttraumatic stress disorder and other trauma symptoms but also a specific evaluation of sleep-related complaints. Similarly, if a history of both trauma and sleep complaints is identified, an effective trauma-informed intervention, whether psychological, psychopharmacologic, or a combination of the two, should directly address sleep issues.


Assuntos
Transtornos do Sono-Vigília , Transtornos de Estresse Pós-Traumáticos , Criança , Humanos , Adolescente , Vigília , Transtornos de Estresse Pós-Traumáticos/psicologia , Medo , Transtornos do Sono-Vigília/complicações , Transtornos do Sono-Vigília/diagnóstico , Sono
2.
Child Adolesc Psychiatr Clin N Am ; 30(1): 225-249, 2021 01.
Artigo em Inglês | MEDLINE | ID: mdl-33223064

RESUMO

Traumatic experiences and sleep disturbances are both common in children and adolescents. Because of the reciprocal relationship between sleep complaints and trauma, a mental health evaluation should include not only an assessment of posttraumatic stress disorder and other trauma symptoms but also a specific evaluation of sleep-related complaints. Similarly, if a history of both trauma and sleep complaints is identified, an effective trauma-informed intervention, whether psychological, psychopharmacologic, or a combination of the two, should directly address sleep issues.


Assuntos
Transtornos do Sono-Vigília , Transtornos de Estresse Pós-Traumáticos , Adolescente , Criança , Humanos , Sono , Transtornos do Sono-Vigília/etiologia , Inquéritos e Questionários , Vigília
3.
Bipolar Disord ; 5(5): 370-4, 2003 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-14525559

RESUMO

BACKGROUND: Oxcarbazepine (10-keto-carbamazepine) appears to be better tolerated and simpler to use than carbamazepine. It has antimanic effects but, as its potential clinical usefulness and tolerability in broad samples of psychiatric patients remain to be tested, we reviewed both the pharmacology of oxcarbazepine and our early experience with this new agent among psychiatric inpatients. METHODS: We reviewed medical records of all inpatients given oxcarbazepine in the first 15 months of its use at McLean Hospital. Data analyzed included dosing, presenting illnesses, other medications, clinical changes, and adverse effects. RESULTS: Oxcarbazepine was given to 56 inpatients (1.3% of admissions; 31 women, 25 men) presenting with depression (n = 23), mania (n = 19), or psychosis (n = 14). The discharge daily dose for the 43 patients (76%) taking oxcarbazepine was 831 mg/day, 34% higher in men than women, and fell by 9 mg/year-of-age. Oxcarbazepine was the only putative mood-stabilizing agent given at discharge in 19 of 43 cases (44%). It was discontinued in 20% of patients for apparent inefficacy, and 4% for adverse effects. Changes in CGI and GAF scores were similarly high across illnesses, and unrelated to days of use of oxcarbazepine or its dose. CONCLUSIONS: Oxcarbazepine was well tolerated and simpler to use clinically than its precursor carbamazepine. This agent should be studied in controlled trials to test its efficacy in specific types of major psychiatric disorders, and particularly for long-term maintenance treatment in bipolar disorder.


Assuntos
Transtorno Bipolar/tratamento farmacológico , Carbamazepina/análogos & derivados , Carbamazepina/uso terapêutico , Fatores Etários , Anticonvulsivantes/uso terapêutico , Quimioterapia Combinada , Feminino , Seguimentos , Humanos , Pacientes Internados , Masculino , Oxcarbazepina , Escalas de Graduação Psiquiátrica , Estudos Retrospectivos , Índice de Gravidade de Doença , Resultado do Tratamento
4.
Am J Psychiatry ; 160(7): 1348-50, 2003 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-12832255

RESUMO

OBJECTIVE: The authors compared the new extended-release and standard preparations of divalproex sodium. METHOD: Twelve patients with DSM-IV bipolar disorder or schizoaffective disorder who were clinically stable while taking the standard form of divalproex participated in the study. These patients were given a single daily dose of the extended-release preparation of divalproex in an open 6-week trial. Clinical symptoms and adverse effects were rated weekly. Doses were adjusted to maintain steady serum valproate concentrations. RESULTS: The medication change was associated with negligible changes in clinical status and tolerability. To maintain serum drug levels, however, 21% higher doses of the extended-release preparation were required. CONCLUSIONS: Use of extended-release divalproex once a day was as well tolerated as the standard preparation, with no change in efficacy within 6 weeks, but the daily dose needed to maintain stable serum valproic acid concentration was 21% higher.


Assuntos
Antimaníacos/uso terapêutico , Transtorno Bipolar/tratamento farmacológico , Transtornos Psicóticos/tratamento farmacológico , Ácido Valproico/uso terapêutico , Assistência Ambulatorial , Transtorno Bipolar/sangue , Preparações de Ação Retardada , Esquema de Medicação , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Transtornos Psicóticos/sangue , Resultado do Tratamento , Ácido Valproico/sangue , Ácido Valproico/farmacocinética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA